Aleena Amir Malik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aleena Amir Malik has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Amir Hamza Khan
Department of Medicine, Shifa College of Medicine, Islamabad, Pakistan
2 shared publicationsAsia Batool
Department of Medicine, Sir Syed College of Medical Sciences, Karachi, Sindh, Pakistan
2 shared publications- Fatima Sajjad
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
2 shared publications - Kashif Yousaf
Department of Medicine, Jalal-Abad State University named after B. Osmonov Medical Faculty, Jalal-Abad, Kyrgyzstan
2 shared publications Pari Kotak
Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Sindh, Pakistan
2 shared publications- Abdul Basit
Gomal Medical College Dera Ismail Khan Pakistan
1 shared publication
Latest Publications
- 23 October 2026
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
Long-Term Clinical Outcomes of Left Atrial Appendage Closure Versus Oral Anticoagulation in Atrial Fibrillation: An Updated Meta-Analysis and Trial Sequential Analysis
Left atrial appendage closure (LAAC) has emerged as an alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF), particularly among individuals at increased risk of bleeding. We performed an updated systematic review and meta-analysis of randomized controlled trials comparing the efficacy and safety of LAAC versus OAC in AF. PubMed, Embase, and Scopus were searched through May 2026. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model, and trial sequential analysis (TSA) was conducted to evaluate the sufficiency of cumulative evidence. Six randomized trials involving 7,004 patients were included. Compared with OAC, LAAC demonstrated similar risks of stroke, systemic embolism, cardiovascular death, all-cause mortality, and transient ischemic attack. LAAC showed a nominally higher risk of ischemic stroke or systemic embolization (RR 1.36, 95% CI 1.04–1.79), although this finding was not robust to sensitivity analysis, with a borderline increase in ischemic stroke. In contrast, LAAC significantly reduced non-procedural clinically relevant bleeding (RR 0.49, 95% CI 0.42-0.58), while major bleeding and hemorrhagic stroke were comparable between groups. TSA confirmed sufficient evidence supporting the reduction in bleeding outcomes but indicated that current evidence remains insufficient to establish definitive conclusions regarding thromboembolic efficacy. Overall, LAAC was not associated with statistically significant differences in several thromboembolic and mortality outcomes compared with OAC, while providing a substantial reduction in non-procedural clinically relevant bleeding. However, the potential signal toward increased ischemic events warrants further investigation in adequately powered randomized trials, particularly against contemporary DOAC-based therapy.
- 23 October 2026
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
Long-Term Clinical Outcomes of Left Atrial Appendage Closure Versus Oral Anticoagulation in Atrial Fibrillation: An Updated Meta-Analysis and Trial Sequential Analysis
Left atrial appendage closure (LAAC) has emerged as an alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF), particularly among individuals at increased risk of bleeding. We performed an updated systematic review and meta-analysis of randomized controlled trials comparing the efficacy and safety of LAAC versus OAC in AF. PubMed, Embase, and Scopus were searched through May 2026. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model, and trial sequential analysis (TSA) was conducted to evaluate the sufficiency of cumulative evidence. Six randomized trials involving 7,004 patients were included. Compared with OAC, LAAC demonstrated similar risks of stroke, systemic embolism, cardiovascular death, all-cause mortality, and transient ischemic attack. LAAC showed a nominally higher risk of ischemic stroke or systemic embolization (RR 1.36, 95% CI 1.04–1.79), although this finding was not robust to sensitivity analysis, with a borderline increase in ischemic stroke. In contrast, LAAC significantly reduced non-procedural clinically relevant bleeding (RR 0.49, 95% CI 0.42-0.58), while major bleeding and hemorrhagic stroke were comparable between groups. TSA confirmed sufficient evidence supporting the reduction in bleeding outcomes but indicated that current evidence remains insufficient to establish definitive conclusions regarding thromboembolic efficacy. Overall, LAAC was not associated with statistically significant differences in several thromboembolic and mortality outcomes compared with OAC, while providing a substantial reduction in non-procedural clinically relevant bleeding. However, the potential signal toward increased ischemic events warrants further investigation in adequately powered randomized trials, particularly against contemporary DOAC-based therapy.
- Open Access
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (41) , e50994
Metallic versus plastic stents for the management of biliary obstruction
Background: Biliary obstruction can be managed with metallic stents (MS) or plastic stents (PS), but comparative evidence across benign and malignant conditions remains uncertain. We conducted a systematic review and meta-analysis comparing MS and PS. Methods: PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL were searched from inception to the search date. Randomized controlled trials and observational studies comparing MS with PS in patients with benign or malignant biliary obstruction were eligible. Primary analyses compared MS with PS across the overall eligible population, including both benign and malignant obstruction. Where sufficient outcome-specific data were available, subgroup analyses were performed according to disease etiology (benign vs malignant). Outcomes included functional success, adverse events, recurrent biliary obstruction (RBO), procedure time, and overall survival. Meta-analysis was performed with Hartung–Knapp sensitivity analyses. Results: Nine studies comprising 890 participants were included. Functional success was comparable between MS and PS (RR = 1.03, 95% confidence intervals [CI]: 0.96–1.11). Among 8 studies contributing adverse-event data, no significant difference was observed (RR = 1.37, 95% CI: 0.92–2.03; P = .123; I 2 = 45.4%). Adverse events were higher with MS in malignant disease (RR = 1.74, 95% CI: 1.15–2.63) but not benign disease (RR = 1.01, 95% CI: 0.83–1.23; P for subgroup difference = .020). Hartung–Knapp analysis remained non-significant (RR = 1.37, 95% CI: 0.96–1.95; P = .078). MS showed a lower risk of RBO (RR = 0.61, 95% CI: 0.32–1.17; I 2 = 93.1%), supported by Hartung–Knapp analysis (RR = 0.61, 95% CI: 0.41–0.91). Conclusion: MS and PS demonstrated comparable functional success and overall adverse-event rates, although adverse events were higher with MS in malignant disease. MS may improve stent durability, but substantial heterogeneity limits certainty. Available studies did not demonstrate a consistent survival advantage. Further randomized trials are warranted.
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (41) , e50994
Open AccessMetallic versus plastic stents for the management of biliary obstruction
Background: Biliary obstruction can be managed with metallic stents (MS) or plastic stents (PS), but comparative evidence across benign and malignant conditions remains uncertain. We conducted a systematic review and meta-analysis comparing MS and PS. Methods: PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL were searched from inception to the search date. Randomized controlled trials and observational studies comparing MS with PS in patients with benign or malignant biliary obstruction were eligible. Primary analyses compared MS with PS across the overall eligible population, including both benign and malignant obstruction. Where sufficient outcome-specific data were available, subgroup analyses were performed according to disease etiology (benign vs malignant). Outcomes included functional success, adverse events, recurrent biliary obstruction (RBO), procedure time, and overall survival. Meta-analysis was performed with Hartung–Knapp sensitivity analyses. Results: Nine studies comprising 890 participants were included. Functional success was comparable between MS and PS (RR = 1.03, 95% confidence intervals [CI]: 0.96–1.11). Among 8 studies contributing adverse-event data, no significant difference was observed (RR = 1.37, 95% CI: 0.92–2.03; P = .123; I 2 = 45.4%). Adverse events were higher with MS in malignant disease (RR = 1.74, 95% CI: 1.15–2.63) but not benign disease (RR = 1.01, 95% CI: 0.83–1.23; P for subgroup difference = .020). Hartung–Knapp analysis remained non-significant (RR = 1.37, 95% CI: 0.96–1.95; P = .078). MS showed a lower risk of RBO (RR = 0.61, 95% CI: 0.32–1.17; I 2 = 93.1%), supported by Hartung–Knapp analysis (RR = 0.61, 95% CI: 0.41–0.91). Conclusion: MS and PS demonstrated comparable functional success and overall adverse-event rates, although adverse events were higher with MS in malignant disease. MS may improve stent durability, but substantial heterogeneity limits certainty. Available studies did not demonstrate a consistent survival advantage. Further randomized trials are warranted.
- Open Access
- 21 September 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (5) , e70464
Catheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Reduced or Mildly Reduced Ejection Fraction: A GRADE ‐Assessed Systematic Review and Meta‐Analysis
Background: Catheter ablation is an established rhythm‐control strategy for atrial fibrillation (AF), but its effectiveness in patients with heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF) remains incompletely defined. We performed a GRADE‐assessed systematic review and meta‐analysis comparing catheter ablation with conventional medical therapy in this population. Methods: PubMed, Embase, and the Cochrane Library were searched from inception to February 2026. Randomized controlled trials and observational cohort studies enrolling adults with AF and left ventricular ejection fraction (LVEF) ≤ 50% were included. Primary outcomes were all‐cause mortality, cardiovascular mortality, and change in LVEF. Secondary outcomes were change in B‐type natriuretic peptide (BNP) and cardiovascular hospitalization. Random‐effects models were used, and certainty of evidence was assessed using GRADE. Results: Thirteen studies involving 131 492 participants were included. Catheter ablation significantly reduced all‐cause mortality (RR 0.61, 95% CI 0.51–0.71) and cardiovascular mortality (RR 0.46, 95% CI 0.31–0.66), improved LVEF (MD 6.47%, 95% CI 4.47–8.47), and reduced BNP levels (MD −136.85 pg/mL, 95% CI −190.46 to −83.23). No significant reduction was observed in cardiovascular hospitalization (RR 0.78, 95% CI 0.53–1.13). Mortality benefits were consistent across subgroup analyses by study design and baseline LVEF. Conclusions: Catheter ablation was associated with lower mortality and improved cardiac function compared with medical therapy in patients with AF and HFrEF/HFmrEF. Further studies specifically evaluating HFmrEF populations are warranted.
- 21 September 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (5) , e70464
Open AccessCatheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Reduced or Mildly Reduced Ejection Fraction: A GRADE ‐Assessed Systematic Review and Meta‐Analysis
Background: Catheter ablation is an established rhythm‐control strategy for atrial fibrillation (AF), but its effectiveness in patients with heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF) remains incompletely defined. We performed a GRADE‐assessed systematic review and meta‐analysis comparing catheter ablation with conventional medical therapy in this population. Methods: PubMed, Embase, and the Cochrane Library were searched from inception to February 2026. Randomized controlled trials and observational cohort studies enrolling adults with AF and left ventricular ejection fraction (LVEF) ≤ 50% were included. Primary outcomes were all‐cause mortality, cardiovascular mortality, and change in LVEF. Secondary outcomes were change in B‐type natriuretic peptide (BNP) and cardiovascular hospitalization. Random‐effects models were used, and certainty of evidence was assessed using GRADE. Results: Thirteen studies involving 131 492 participants were included. Catheter ablation significantly reduced all‐cause mortality (RR 0.61, 95% CI 0.51–0.71) and cardiovascular mortality (RR 0.46, 95% CI 0.31–0.66), improved LVEF (MD 6.47%, 95% CI 4.47–8.47), and reduced BNP levels (MD −136.85 pg/mL, 95% CI −190.46 to −83.23). No significant reduction was observed in cardiovascular hospitalization (RR 0.78, 95% CI 0.53–1.13). Mortality benefits were consistent across subgroup analyses by study design and baseline LVEF. Conclusions: Catheter ablation was associated with lower mortality and improved cardiac function compared with medical therapy in patients with AF and HFrEF/HFmrEF. Further studies specifically evaluating HFmrEF populations are warranted.
- 17 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain. Methods: PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026. Phase II/III RCTs comparing carboplatin plus standard chemotherapy with standard therapy alone in TNBC were included. Primary outcomes were disease-free survival (DFS), overall survival (OS), and pathological complete response (pCR). Pooled hazard ratios (HRs) and risk ratios (RRs) were calculated using random-effects models. Results: Twenty-three trials (n = 8797) were included. Carboplatin significantly improved DFS (HR 0.68, 95% CI 0.60–0.76), OS (HR 0.65, 95% CI 0.53–0.80), and pCR (RR 1.46, 95% CI 1.30–1.64). Improvements were also observed in distant disease-free survival and recurrence-free survival. However, carboplatin was associated with increased hematological toxicities, including anemia, neutropenia, and thrombocytopenia, and higher rates of dose reduction and treatment discontinuation, though treatment-related mortality was not significant. Conclusion: Carboplatin-containing chemotherapy improves survival outcomes and pCR in TNBC. Despite increased toxicity, adverse effects are generally manageable. These findings support the incorporation of carboplatin into TNBC treatment, with careful patient selection to balance efficacy and safety.
- 17 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain. Methods: PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026. Phase II/III RCTs comparing carboplatin plus standard chemotherapy with standard therapy alone in TNBC were included. Primary outcomes were disease-free survival (DFS), overall survival (OS), and pathological complete response (pCR). Pooled hazard ratios (HRs) and risk ratios (RRs) were calculated using random-effects models. Results: Twenty-three trials (n = 8797) were included. Carboplatin significantly improved DFS (HR 0.68, 95% CI 0.60–0.76), OS (HR 0.65, 95% CI 0.53–0.80), and pCR (RR 1.46, 95% CI 1.30–1.64). Improvements were also observed in distant disease-free survival and recurrence-free survival. However, carboplatin was associated with increased hematological toxicities, including anemia, neutropenia, and thrombocytopenia, and higher rates of dose reduction and treatment discontinuation, though treatment-related mortality was not significant. Conclusion: Carboplatin-containing chemotherapy improves survival outcomes and pCR in TNBC. Despite increased toxicity, adverse effects are generally manageable. These findings support the incorporation of carboplatin into TNBC treatment, with careful patient selection to balance efficacy and safety.
- Open Access
- 15 June 2026
- Published by Springer Nature in Egyptian Journal of Neurosurgery
- Vol. 41 (1)
Transradial versus transfemoral access for diagnostic cerebral angiography: a systematic review and meta-analysis of randomized and prospective studies with grade assessment
Background: Cerebral angiography is the gold standard for the diagnosis of cerebrovascular disease. Transfemoral access (TFA) has been the conventional approach for angiography, but concerns regarding access-site complications have led to the increasing adoption of the transradial approach (TRA). This systematic review and meta-analysis aimed to compare the safety and efficacy of transradial access (TRA) versus transfemoral access (TFA) in patients undergoing diagnostic cerebral angiography (DCA). Method: Following an extensive electronic search of PubMed, Embase, Cochrane and ClinicalTrials.gov, eligible RCTs and prospective observational studies encompassing patients undergoing DCA using TRA and TFA were included in the pooled analysis. Quality was assessed by Rob 2.0 tool and Newcastle-Ottawa scale (NOS) while certainty of evidence was evaluated through GRADE. Dichotomous variables were pooled as risk ratio (RR) and continuous variables as mean difference (MD) with a random effects model. Heterogeneity was assessed using the I² statistic, and sensitivity analyses were conducted when substantial heterogeneity was present. Results: Nine studies (4 RCTs and 5 prospective observational studies) involving 4,827 patients were included. Procedural success was comparable between the TRA and TFA groups. TRA was associated with significantly higher crossover rates (RR 3.03, 95% CI 1.26–7.32; P = 0.01; I 2 = 29%) and a shorter time to ambulation (MD − 14.69 h; P < 0.00001). TRA was associated with significantly lower total complications (RR 0.56, 95%CI 0.34–0.93; P = 0.02), while access-site complications trended to be lower with TRA but did not reach statistical significance (RR 0.40, 95% CI 0.16–1.02; P = 0.06). TRA was associated with longer procedure time (MD + 4.19 min; P < 0.00001), while no significant differences were observed in neurological complications, fluoroscopy time, contrast volume, or radiation dose. The certainty of evidence ranged from moderate to low. Conclusion: TRA and TFA demonstrated comparable safety and procedural efficacy for diagnostic cerebral angiography. While TRA is associated with higher crossover rates and slightly longer procedure times, it offers the important advantages of earlier ambulation and is associated with fewer overall complications. Access selection should be guided by the patient characteristics, operator experience, and institutional expertise. Further adequately powered randomized controlled trials are warranted to validate these findings and clarify the optimal access strategy.
- 15 June 2026
- Published by Springer Nature in Egyptian Journal of Neurosurgery
- Vol. 41 (1)
Open AccessTransradial versus transfemoral access for diagnostic cerebral angiography: a systematic review and meta-analysis of randomized and prospective studies with grade assessment
Background: Cerebral angiography is the gold standard for the diagnosis of cerebrovascular disease. Transfemoral access (TFA) has been the conventional approach for angiography, but concerns regarding access-site complications have led to the increasing adoption of the transradial approach (TRA). This systematic review and meta-analysis aimed to compare the safety and efficacy of transradial access (TRA) versus transfemoral access (TFA) in patients undergoing diagnostic cerebral angiography (DCA). Method: Following an extensive electronic search of PubMed, Embase, Cochrane and ClinicalTrials.gov, eligible RCTs and prospective observational studies encompassing patients undergoing DCA using TRA and TFA were included in the pooled analysis. Quality was assessed by Rob 2.0 tool and Newcastle-Ottawa scale (NOS) while certainty of evidence was evaluated through GRADE. Dichotomous variables were pooled as risk ratio (RR) and continuous variables as mean difference (MD) with a random effects model. Heterogeneity was assessed using the I² statistic, and sensitivity analyses were conducted when substantial heterogeneity was present. Results: Nine studies (4 RCTs and 5 prospective observational studies) involving 4,827 patients were included. Procedural success was comparable between the TRA and TFA groups. TRA was associated with significantly higher crossover rates (RR 3.03, 95% CI 1.26–7.32; P = 0.01; I 2 = 29%) and a shorter time to ambulation (MD − 14.69 h; P < 0.00001). TRA was associated with significantly lower total complications (RR 0.56, 95%CI 0.34–0.93; P = 0.02), while access-site complications trended to be lower with TRA but did not reach statistical significance (RR 0.40, 95% CI 0.16–1.02; P = 0.06). TRA was associated with longer procedure time (MD + 4.19 min; P < 0.00001), while no significant differences were observed in neurological complications, fluoroscopy time, contrast volume, or radiation dose. The certainty of evidence ranged from moderate to low. Conclusion: TRA and TFA demonstrated comparable safety and procedural efficacy for diagnostic cerebral angiography. While TRA is associated with higher crossover rates and slightly longer procedure times, it offers the important advantages of earlier ambulation and is associated with fewer overall complications. Access selection should be guided by the patient characteristics, operator experience, and institutional expertise. Further adequately powered randomized controlled trials are warranted to validate these findings and clarify the optimal access strategy.
- Open Access
- 1 November 2025
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (11)
Parenchyma-sparing resection for a complex jejunal duplication with a shared mesenteric blood supply: a case report
Gastrointestinal (GI) duplication cysts present significant diagnostic and surgical challenges, particularly with complex anatomy. We report a 2-year-old male with chronic obstructive symptoms caused by a mixed-type jejunal duplication. While initial ultrasound was equivocal, contrast-enhanced computed tomography delineated a cystic mass on the mesenteric border, guiding surgical planning. Intraoperatively, a shared mesenteric blood supply with the native jejunum precluded complete resection. A parenchyma-sparing partial excision of the symptomatic, non-communicating portion was performed, preserving the fused communicating segment. Histology confirmed the diagnosis. The patient’s recovery was uneventful, with complete symptom resolution at follow-up. This case illustrates that for complex GI duplications, a tailored, parenchyma-sparing resection is a safe and effective strategy when vascular integrity is at risk, shifting the clinical focus from acute management to the necessity of long-term surveillance for the retained segment.
- 1 November 2025
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (11)
Open AccessParenchyma-sparing resection for a complex jejunal duplication with a shared mesenteric blood supply: a case report
Gastrointestinal (GI) duplication cysts present significant diagnostic and surgical challenges, particularly with complex anatomy. We report a 2-year-old male with chronic obstructive symptoms caused by a mixed-type jejunal duplication. While initial ultrasound was equivocal, contrast-enhanced computed tomography delineated a cystic mass on the mesenteric border, guiding surgical planning. Intraoperatively, a shared mesenteric blood supply with the native jejunum precluded complete resection. A parenchyma-sparing partial excision of the symptomatic, non-communicating portion was performed, preserving the fused communicating segment. Histology confirmed the diagnosis. The patient’s recovery was uneventful, with complete symptom resolution at follow-up. This case illustrates that for complex GI duplications, a tailored, parenchyma-sparing resection is a safe and effective strategy when vascular integrity is at risk, shifting the clinical focus from acute management to the necessity of long-term surveillance for the retained segment.